Vigil Neuroscience hits Wall Street with two ex-Amgen TREM2 agonists

Big Pharma largely abandoned neuroscience over the last several years — but the folks at Vigil Neuroscience believe a renaissance is around the corner, and apparently, so do investors.

The Cambridge, MA-based startup closed a $98 million IPO on Tuesday, pricing 7 million shares at $14, just below an expected...

Click to view original post